BrainStorm Cell Therapeutics Initiates Stem Cell Safety Study in Primates for Parkinson’s Disease
News Feb 15, 2007
BrainStorm Cell Therapeutics has announced that it has initiated a safety trial using an animal model of Parkinson’s disease in primates.
The study utilizes BrainStorm’s adult stem cell technology which has shown efficacy in animal models of Parkinson’s Disease in previous pre-clinical trials.
In those studies, human-bone-marrow-derived stem cells were differentiated into astrocyte-like cells (supporting cells) and transplanted into mice and rats brains. The engrafted cells survived, kept their function and significantly improved the motor symptoms of Parkinson's Disease animal models over a long period of time.
The study is being carried out in collaboration with the Center for Applied Medical Research (CIMA) of the University of Navarra in Pamplona, Spain. The team at the Movement Disorders Unit at the University has over 20 years experience in researching and applying new therapies to treat Parkinson’s Disease, and anticipates being among the first to use BrainStorm’s technology to treat patients in its own University Hospital.
Commenting on the announcement, Yoram Drucker, BrainStorm Cell Therapeutic’s Chief Operating Officer stated: “We are pleased to have this primate safety study underway and we anticipate that successful results will lead to human clinical trials.”
In addition to moving ahead with the company’s Parkinson’s Disease program, BrainStorm is also progressing with pre-clinical trials applying the company’s stem cell technology to the treatment of ALS and Multiple Sclerosis.
Scientists have used machine learning to train computers to see parts of the cell the human eye cannot easily distinguish. Using 3D images of fluorescently labeled cells, the research team taught computers to find structures inside living cells without fluorescent labels, using only black and white images generated by an inexpensive technique known as brightfield microscopy.READ MORE
The National Institutes of Health announced the launch of a new initiative to help speed the development of cures for sickle cell disease. The Cure Sickle Cell Initiative will take advantage of the latest genetic discoveries and technological advances to move the most promising genetic-based curative therapies safely into clinical trials within five to 10 years.